Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.

TitleGenomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Publication TypeJournal Article
Year of Publication2015
AuthorsFrank, TS, Sun, X, Zhang, Y, Yang, J, Fisher, WE, Gingras, M-C, Li, M
JournalCancer Lett
Volume363
Issue1
Pagination1-6
Date Published2015 Jul 10
ISSN1872-7980
KeywordsAnimals, Antineoplastic Agents, Biomarkers, Tumor, Drug Resistance, Neoplasm, Gene Expression Profiling, Genetic Predisposition to Disease, Genomics, Humans, Molecular Targeted Therapy, Pancreatic Neoplasms, Patient Selection, Pharmacogenetics, Phenotype, Precision Medicine, Predictive Value of Tests, Signal Transduction
Abstract

Pancreatic cancer has the worst five-year survival rate of all malignancies due to its aggressive progression and resistance to therapy. Current therapies are limited to gemcitabine-based chemotherapeutics, surgery, and radiation. The current trend toward "personalized genomic medicine" has the potential to improve the treatment options for pancreatic cancer. Gene identification and genetic alterations like single nucleotide polymorphisms and mutations will allow physicians to predict the efficacy and toxicity of drugs, which could help diagnose pancreatic cancer, guide neoadjuvant or adjuvant treatment, and evaluate patients' prognosis. This article reviews the multifaceted roles of genomics and pharmacogenomics in pancreatic cancer.

DOI10.1016/j.canlet.2015.04.009
Alternate JournalCancer Lett.
PubMed ID25890222
PubMed Central IDPMC4451193
Grant ListR01 CA138701 / CA / NCI NIH HHS / United States
U54 HG003273 / HG / NHGRI NIH HHS / United States
R01CA138701 / CA / NCI NIH HHS / United States